CDKN2A and cancer: CGH of 10 different cell lines revealed that the loss of the p16Ink4a/p19Arf-locus was the only common signature where the RT2.Cdkn2a−/−- or the RT2.CRISPR-Cdkn2a-cancer cells differed from the parental or the CRISPR-Cas9 control cell lines (Supplementary Fig. 5a, b).